HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Luye Pharma (2186.HK) - Could the Magic of Hillhouse Last Long?

InnoCare Pharma Ltd (9969.HK) - What Attracts Both Hillhouse and Vivo Capital?

Industry Report - Insights on China Pet Medical Industry

Pre-IPO Adagene Inc (ADAG US) - Advanced Technology but Still Take Time for Commercialization

Sihuan Pharmaceutical (460 HK) - The Logic Behind the Rally of the Stock Price

Pre-IPO BeiGene - Would the IPO on the STAR Market Be the Last Hurrah?

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Capital Markets

Sciclone Pharmaceuticals / Equity Capital Markets

<p>On February 1, 2021, according to the disclosure of the HKEX, <a href="https://www.smartkarma.com/entities/sciclone-pharmaceuticals-inc" target="_blank" data-smartkarma-citation="entities:17351:1" rel="noopener">Sciclone Pharmaceuticals, Inc (SCLN US)</a> passed the hearing of HKEX and will be listed on the main board. SciClone is a biopharmaceutical company with an integrated platform for product development and commercialization, focusing on therapeutic areas including oncology and severe infections. SciClone is reportedly looking to raise $400 million, which would be primarily used to acquire or license-in new drug candidates in China or other global markets, repay existing debt, and drive the development and commercialization of clinical drug candidates.</p>

On February 1, 2021, according to the disclosure of the HKEX, Sciclone Pharmaceuticals, Inc (SCLN US) passed the hearing of HKEX and will be listed on the main board. SciClone is a biopharmaceutical company with an integrated platform for product development and commercialization, focusing on therapeutic areas including oncology and severe infections. SciClone is reportedly looking to raise $400 million, which would be primarily used to acquire or license-in new drug candidates in China or other global markets, repay existing debt, and drive the development and commercialization of clinical drug candidates.

Pre-IPO SciClone Pharmaceuticals - Here Are the Strength and the Concerns